Paediatrics and Child Health and INFANT Centre, University College Cork, Cork, Ireland.
Applied Psychology, University College Cork, Cork, Ireland.
Pediatr Allergy Immunol. 2019 Dec;30(8):810-816. doi: 10.1111/pai.13108. Epub 2019 Aug 29.
BACKGROUND: Many breastfed babies in Ireland receive formula supplementation within 24 hours of birth. We explored (a) impact of formula supplementation on the likelihood of developing cow's milk protein allergy (CMPA) and (b) current practice of formula supplementation (<24 hours) among mothers intending to breastfeed. METHOD: Fifty-five CMPA-diagnosed children, fed at <24 hours of age (breast only, formula only or breast with formula supplementation), were recruited, and 55 milk-tolerant age- and sex-matched controls were identified retrospectively in Cork University Maternity Hospital. Two logistic regressions (LoR) examined neonatal feed types on likelihood of developing CMPA while controlling for parental atopy and infant sex. Formula supplementation was then prospectively measured among a separate group of 179 breastfeeding mothers. Linear regression (LiR) analysis was used to examine the subjective and objective reasons for formula supplementation, in addition to examining pre-existing factors. RESULTS: Two LoR examined the infant groups: exclusively breastfed, exclusively formula-fed or breastfed with formula supplementation. The first LoR model which showed only formula supplementation was significant in prediction of development of CMPA (χ (3) = 25.74, P < .05), with 74% diagnostic accuracy when parental atopy and infant sex were controlled for. Breastfed infants given formula supplements were 7.03 (95% CI, 1.82-27.25) times more likely to exhibit CMPA than those who were exclusively breastfed. Formula supplementation was significant (OR 16.62, 95% CI 3.89-71.11), indicating that breastfed infants who were given formula supplements were 16 times more likely to exhibit CMPA than those who were exclusively bottle-fed. Exclusively formula-fed infants (odds ratio 0.42, 95% CI, 0.16-1.07) were not significantly more likely to exhibit CMPA than those who were exclusively breastfed in either model (P > .05). About 45.8% of breastfed infants (<24 hours) received supplemental formula. LiR investigated importance of the subjective and objective reasons, in predicting formula supplementation. This model was significant F(8,170) = 66.95, P < .05) explaining 75% of total variance. The subjective factors 'no latch' and 'mum unwell' were the strongest predictors (β > .45). Objective factors and pre-existing factors had lower ß values with only mode of delivery and infant hypoglycaemia being significant. CONCLUSION: Breastfed babies are still being put at significantly increased risk of CMPA by receiving supplemental formula in the first 24 hours of life, despite the major predictors of supplementation being subjective and remediable in other ways. Mothers and healthcare providers should be better educated on the benefits of exclusive breastfeeding and resourced adequately to avoid unnecessary formula supplementation to reduce risk of development of CMPA.
背景:在爱尔兰,许多母乳喂养的婴儿在出生后 24 小时内接受配方奶粉补充。我们探讨了(a)配方奶粉补充对发展牛奶蛋白过敏(CMPA)的可能性的影响,以及(b)打算母乳喂养的母亲中当前的配方奶粉补充(<24 小时)做法。 方法:在科克大学妇产医院招募了 55 名 CMPA 确诊的儿童,他们在<24 小时的年龄(仅母乳喂养、仅配方奶喂养或母乳喂养加配方奶补充)时接受喂养,并回顾性地确定了 55 名牛奶耐受的年龄和性别匹配的对照者。两个逻辑回归(LoR)在控制父母特应性和婴儿性别后,检查了新生儿喂养类型与发展 CMPA 的可能性之间的关系。然后,在 179 名母乳喂养的母亲中前瞻性地测量了配方奶补充。线性回归(LiR)分析用于检查配方奶补充的主观和客观原因,以及检查预先存在的因素。 结果:两个 LoR 检查了婴儿组:完全母乳喂养、完全配方奶喂养或母乳喂养加配方奶补充。第一个仅显示配方奶补充的 LoR 模型在预测 CMPA 的发展方面具有显著意义(χ (3) = 25.74,P <.05),当控制父母特应性和婴儿性别时,其诊断准确率为 74%。接受配方奶补充的母乳喂养婴儿出现 CMPA 的可能性是仅母乳喂养婴儿的 7.03 倍(95%CI,1.82-27.25)。配方奶补充具有统计学意义(OR 16.62,95%CI 3.89-71.11),表明接受配方奶补充的母乳喂养婴儿出现 CMPA 的可能性是仅奶瓶喂养婴儿的 16 倍。完全配方奶喂养的婴儿(优势比 0.42,95%CI,0.16-1.07)与仅母乳喂养的婴儿相比,出现 CMPA 的可能性没有显著增加,在两个模型中均无统计学意义(P >.05)。大约 45.8%的母乳喂养婴儿(<24 小时)接受了补充配方奶。LiR 调查了主观和客观原因的重要性,以预测配方奶补充。该模型具有统计学意义(F(8,170)= 66.95,P <.05),解释了总方差的 75%。主观因素“无 latch”和“妈妈身体不适”是最强的预测因素(β>.45)。客观因素和预先存在的因素的β值较低,只有分娩方式和婴儿低血糖具有统计学意义。 结论:尽管补充的主要预测因素是主观的,可以通过其他方式纠正,但母乳喂养的婴儿在生命的头 24 小时内仍通过接受补充配方奶而面临显著增加的 CMPA 风险。母亲和医疗保健提供者应接受有关纯母乳喂养益处的更好教育,并获得足够的资源,以避免不必要的配方奶补充,从而降低 CMPA 发展的风险。
Pediatr Allergy Immunol. 2019-8-29
Pediatr Allergy Immunol. 1994
J Hum Nutr Diet. 2022-6
Allergol Immunopathol (Madr). 2006
JPEN J Parenter Enteral Nutr. 2018-11-19
Arch Pediatr. 2012-3
Acta Paediatr Scand. 1979-9
Matern Child Health J. 2025-2
Clin Transl Allergy. 2024-4
Transl Pediatr. 2022-9
Rev Saude Publica. 2021